ViewRay Announces Collaborations with Elekta and Medtronic

Go back to ViewRay Announces Collaborations with Elekta and Medtronic

Guggenheim Reiterates Buy Rating on ViewRay Inc. (VRAY)

December 3, 2019 9:01 AM EST

Guggenheim analyst Christopher Pasquale reiterated a Buy rating and $8.00 price target on ViewRay Inc. (NASDAQ: VRAY) after the company announced that it has entered into strategic collaborations with both Elekta (EKTAF) and MDT as part of a planned equity financing.

The analyst... More

Baird Reiterates Outperform Rating on ViewRay Inc. (VRAY); 'Financing Monkey Off the Back'

December 3, 2019 8:54 AM EST

Baird analyst Jason Bednar reiterated an Outperform rating and $6.00 price target on ViewRay Inc. (NASDAQ: VRAY) after the company announced proposed financing details, including a $75M raise in which Fosun, Elekta, and Medtronic will participate. As part of their investments, VRAY will partner... More

ViewRay (VRAY) to Resume Trading at 4:30 pm

December 2, 2019 4:14 PM EST

ViewRay (NASDAQ: VRAY) to Resume Trading at 4:30 pm

... More

ViewRay (VRAY) Announces Proposed $75M Public Offering of Common Stock

December 2, 2019 4:03 PM EST

ViewRay, Inc. (Nasdaq: VRAY), maker of the MRIdian, which combines MRI and external-beam radiation therapy to simultaneously image and treat cancer patients, today announced that it has commenced an underwritten public offering of $75.0 million of shares of its common stock. In addition, ViewRay expects to grant the... More

ViewRay (VRAY) Halted for News Disseminated

December 2, 2019 4:02 PM EST

ViewRay (NASDAQ: VRAY) Halted for News Disseminated

... More